Technology Offerings

Magnetic closure system

The present innovation provides lid and housing of a container with magnets in order to connect those reversibly and safely with each other.

SOTOS – Silent Operating Theatre Optimisation System

New technical solution to manage targeted communication between team members and to minimize noise in the operating theatre. This reduces stress for the operating staff and concomitantly mistakes. We offer the Silent Operating Theatre Optimisation System – “SOTOS”. Prototype tested and available.

Online measurement of deposits in high temperature furnaces/ power plant boilers

The Institute of Combustion and Power Plant Technology (IFK) of the University of Stuttgart has developed a measuring device for use in coal power plants. The device allows for permanent monitoring of the conditions inside the boiler, particularly of soot deposition.
Besides determining the deposition rate inside the boiler, growth characteristics, adhesion, ash qualities and waste disposal behavior with deposit as well as the extent to which these can be cleaned using soot blowers can be judged. Thus, the measuring device can indicate potential for optimization, e.g. of coal compositon in the fuel feed.
The prototype has been tested successfully.

X-ray and Gamma-ray sources based on relativistic Thomson backscattering

The new method allows high laser intensities of any level. Thus, the novel backscattering sources generate X and Gamma-radiation with highest brilliance and intensity and low bandwidth.

In vivo diagnosis and therapeutic control tool of VEGF in retinal disorders

The technology comprises a method for determination of VEGF (vascular endothelial growth factor) concentration directly in vivo in the eye by use of an implantable, semi-permeable biosensor.

New immunostimulatory synthetic compounds for the Treatment of Leishmaniasis and Tuberculosis

The current treatments for tuberculosis and leishmaniosis have many drawbacks: long treatment duration,appearance of resistances,toxic side effects. Our new treatment suggests an immune activator based on a synthetic analogue of an active glycolipid.

Page
1 15 16 17 18 19 518